R Squared’s ClearPoint Neuro CLPT Stock Holding History

R Squared’s Portfolio CLPT Stock Details CLPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-2,050	Closed	-$31.5K	–	538
2024 Q4	$31.5K	Buy	+2,050	New	+$26.6K	0.03%	680

Other funds holding CLPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

EIM

Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

CWM

Cahill Wealth Management Portage, Michigan $196M AUM 8.5% 1-Year Est. Return

R Squared's CLPT Position: Q1 2025 in Review

R Squared sold out of ClearPoint Neuro (CLPT) in Q1 2025, closing a stake of 2,050 shares — an estimated $31.5K sold.

R Squared first reported a position in CLPT in Q4 2024 and held it in 1 quarter. The position peaked at $31.5K in Q4 2024. 101 funds tracked by Wall St. Rank hold CLPT as of Q1 2025.

R Squared reported no remaining ClearPoint Neuro position as of Q1 2025 after selling out during the quarter.
R Squared sold 2,050 ClearPoint Neuro shares in Q1 2025, an estimated $31.5K.
R Squared first reported a position in ClearPoint Neuro in Q4 2024 and held it in 1 quarter.
R Squared's ClearPoint Neuro position peaked at $31.5K in Q4 2024.
101 funds tracked by Wall St. Rank held ClearPoint Neuro as of Q1 2025.

Based on R Squared's 13F filing for Q1 2025, filed 9 May 2025.